{ "schemaVersion": 2, "eyebrow": "Hepatology", "title": "Cirrhotic Ascites Diuretics", "summary": "Use sodium restriction and spironolactone-based diuresis for uncomplicated moderate ascites, but stop or de-escalate therapy when renal, neurologic, or electrolyte toxicity emerges. Refractory ascites requires early transition to large-volume paracentesis with albumin, TIPS selection, and transplant evaluation.", "seoDescription": "Physician guide to diuretic use, monitoring, toxicity management, and escalation to paracentesis, TIPS, and transplant for cirrhotic ascites.", "clinicalQuestion": "How should physicians initiate, monitor, discontinue, and escalate diuretic therapy for ascites caused by cirrhosis?", "specialty": "Hepatology", "audience": "U.S. physicians and medical trainees", "tags": [ "cirrhotic ascites", "spironolactone", "furosemide", "refractory ascites", "large-volume paracentesis", "albumin", "TIPS" ], "keyTakeaways": [ "For grade 2 ascites, use dietary sodium restriction plus diuretics; grade 3 tense ascites should undergo large-volume paracentesis before restriction and diuretics unless the patient has refractory ascites. [22]", "Limit diuretic-associated weight loss to 0.5 kg/day without peripheral edema and 1 kg/day when edema is present; reduce to the lowest effective dose after ascites largely resolves. [20]", "Refractory ascites includes failure to mobilize fluid despite 2 g/day sodium restriction and maximum tolerated spironolactone 400 mg/day plus furosemide 160 mg/day, rapid recurrence after paracentesis, or diuretic-related toxicity. [23]", "Discontinue diuretics for refractory ascites when urine sodium excretion on therapy is not greater than 30 mmol/day, and discontinue permanently after diuretic-induced encephalopathy, renal impairment, or electrolyte abnormalities. [19][22]", "Repeated large-volume paracentesis with albumin 8 g per liter removed is first-line treatment for refractory ascites; consider TIPS in carefully selected patients and evaluate for liver transplantation. [19][22][3]" ], "sections": [ { "id": "select-patients-for-diuresis", "eyebrow": "Initial branch point", "heading": "Choose diuretics by ascites severity and immediate risk", "intro": "The key initial decision is whether ascites is uncomplicated and diuretic-responsive or requires drainage and escalation.", "paragraphs": [ "Perform diagnostic paracentesis with ascitic fluid analysis when evaluating ascites; it is a rapid, cost-effective method to establish the cause and detect ascitic fluid infection. [14][17] A polymorphonuclear neutrophil count of at least 250 cells/mm³ identifies spontaneous bacterial peritonitis in the absence of secondary peritonitis and shifts management away from routine outpatient diuretic titration toward infection-directed treatment and prevention of renal deterioration. [8]", "Grade 1 ascites, detectable only by ultrasound, requires no ascites-specific treatment. Grade 2 ascites, producing moderate symmetric abdominal distension, should be managed with sodium restriction and diuretics. Grade 3 ascites, with marked abdominal distension, should undergo complete large-volume paracentesis in a single session, followed by sodium restriction and oral diuretics unless ascites is refractory. [22][20]", "Do not treat every increase in abdominal girth as uncomplicated portal-hypertensive ascites. Infection, hepatorenal syndrome, progressive azotemia, clinically important electrolyte disturbance, or hepatic encephalopathy changes the risk-benefit balance against further diuretic escalation. These complications define diuretic-intractable ascites when they preclude effective dosing. [23][22]" ], "bullets": [ "Obtain ascitic fluid cell count to identify neutrocytic ascites; PMN count at least 250 cells/mm³ supports spontaneous bacterial peritonitis. [8]", "Use large-volume paracentesis rather than attempting slow outpatient diuresis for tense grade 3 ascites. [20][22]", "Treat new or worsening encephalopathy, renal impairment, or progressive electrolyte imbalance as a diuretic-limiting event. [23][22]" ], "subsections": [], "table": { "caption": "Ascites grade directs the initial use of diuretics and paracentesis. [20][22]", "columns": [ "Clinical state", "Action", "What changes the plan" ], "rows": [ [ "Grade 1: ultrasound-only ascites", "No ascites-specific treatment. [22]", "Progression to clinically apparent ascites warrants reassessment. [22]" ], [ "Grade 2: moderate symmetric distension", "Start sodium restriction and diuretics. [22]", "Slow or stop escalation for renal impairment, encephalopathy, or electrolyte toxicity. [23][22]" ], [ "Grade 3: tense or gross ascites", "Perform complete large-volume paracentesis in one session, then sodium restriction and diuretics if not refractory. [20][22]", "If refractory, use repeated large-volume paracentesis plus albumin rather than continued ineffective diuresis. [19][22]" ], [ "Refractory or diuretic-intractable ascites", "Use repeated large-volume paracentesis plus albumin; assess TIPS candidacy and transplantation. [19][22][3]", "Avoid persistent diuretic exposure when urine sodium response is inadequate or toxicity has occurred. [19][22]" ] ] } }, { "id": "initiate-and-titrate-diuretics", "eyebrow": "Outpatient management", "heading": "Use spironolactone and furosemide to achieve controlled net fluid loss", "intro": "Titrate to clinical response without exceeding a safe daily rate of weight reduction.", "paragraphs": [ "For ascites requiring pharmacologic mobilization, the refractory-ascites ceiling used to judge adequate diuretic exposure is spironolactone 400 mg/day and furosemide 160 mg/day, provided those doses are tolerated; adverse effects frequently prevent reaching those maxima. [23] Inability to mobilize ascites despite sodium restriction and maximum tolerated doses supports diuretic-resistant ascites rather than an indication for indefinite dose escalation. [23]", "Track body weight as the operational measure of diuretic intensity. During diuretic therapy, target no more than 0.5 kg/day weight loss when peripheral edema is absent and no more than 1 kg/day when edema is present. [20] Once ascites has largely resolved, reduce the regimen to the lowest effective dose rather than maintaining high-dose diuresis. [20]", "Assess adherence to a sodium-restricted diet before labeling ascites diuretic-resistant. Refractory ascites is defined in part by inability to mobilize fluid despite dietary sodium restriction of 2 g/day and maximum tolerated diuretics. [23] Rapid fluid reaccumulation after therapeutic paracentesis despite restriction also meets a refractory pattern and should prompt a procedural strategy rather than repeated medication intensification. [23]" ], "bullets": [ "Use spironolactone up to 400 mg/day and furosemide up to 160 mg/day only as tolerated when testing whether ascites is diuretic responsive. [23]", "Cap daily weight loss at 0.5 kg without edema and 1 kg with edema. [20]", "After effective mobilization, taper to the lowest diuretic dose that maintains control. [20]", "Document 2 g/day dietary sodium restriction before concluding that ascites is diuretic resistant. [23]" ], "subsections": [], "table": { "caption": "Diuretic response and toxicity determine whether to continue, reduce, or abandon pharmacologic fluid mobilization. [20][22][23]", "columns": [ "Finding during therapy", "Interpretation", "Next action" ], "rows": [ [ "Weight loss within 0.5 kg/day without edema or 1 kg/day with edema", "Rate is within recommended limits. [20]", "Continue clinical monitoring and adjust toward the lowest effective dose as ascites resolves. [20]" ], [ "Ascites cannot be mobilized despite 2 g/day sodium restriction and maximum tolerated spironolactone 400 mg/day plus furosemide 160 mg/day", "Diuretic-resistant refractory ascites. [23]", "Transition to repeated large-volume paracentesis plus albumin; assess TIPS and transplantation. [19][22][3]" ], [ "Progressive azotemia, hepatic encephalopathy, or progressive electrolyte imbalance", "Diuretic-intractable ascites. [23]", "Stop or reduce diuretics; manage the complication and use non-diuretic ascites control. [22][23]" ], [ "Urine sodium excretion not greater than 30 mmol/day on diuretics in refractory ascites", "Insufficient natriuretic response to justify ongoing diuretics. [19][22]", "Discontinue diuretics and manage with paracentesis plus albumin; consider TIPS if appropriate. [19][22]" ] ] } }, { "id": "monitor-and-manage-toxicity", "eyebrow": "Safety surveillance", "heading": "Stop diuretics when circulatory, renal, neurologic, or sodium complications outweigh natriuresis", "intro": "Monitoring is intended to identify patients in whom continued diuresis will worsen effective arterial hypovolemia or renal dysfunction.", "paragraphs": [ "Reassess renal function, serum sodium, clinical volume status, and encephalopathy during dose adjustment and after any acute decompensating event. Progressive azotemia, hepatic encephalopathy, and progressive electrolyte imbalance are specific diuretic-related complications that establish diuretic-intractable ascites. [23] In refractory ascites, permanently discontinue diuretics after diuretic-induced hepatic encephalopathy, renal impairment, or electrolyte abnormalities. [22]", "For hypovolemic hyponatremia developing during diuretic therapy, discontinue diuretics and expand plasma volume with normal saline. [24] Restrict fluids to 1 to 1.5 L/day only in clinically hypervolemic patients with severe hyponatremia, defined as serum sodium below 125 mmol/L; routine fluid restriction is not the stated intervention for other ascites states. [24] Reserve 3% hypertonic saline for severely symptomatic acute hyponatremia and correct serum sodium slowly. [24]", "Nonselective beta-blocker therapy is not automatically contraindicated by refractory ascites, but identify circulatory failure before maintaining the drug. Continue an otherwise indicated nonselective beta-blocker with close monitoring; reduce the dose or discontinue it when hypotension or acute/progressive renal dysfunction develops. [24] Earlier guidance also advises avoiding high-dose propranolol above 80 mg/day in refractory ascites. [19]" ], "bullets": [ "Stop diuretics and give normal saline for hypovolemic hyponatremia during diuretic therapy. [24]", "Use fluid restriction of 1 to 1.5 L/day only for hypervolemic severe hyponatremia with sodium below 125 mmol/L. [24]", "Use 3% saline only for severely symptomatic acute hyponatremia, with slow correction. [24]", "Reduce or stop nonselective beta-blockers if hypotension or acute/progressive renal dysfunction develops. [24]" ], "subsections": [ { "heading": "When diuretics should not be restarted automatically", "paragraphs": [ "After a diuretic-induced complication, restart only if a meaningful natriuretic response is expected and treatment can be tolerated. In refractory ascites, continuation is supported only when urinary sodium excretion on treatment exceeds 30 mmol/day; otherwise, repeated large-volume paracentesis with albumin becomes the preferred fluid-control strategy. [22][19]" ], "bullets": [] } ], "table": { "caption": "Specific toxicity patterns require different immediate actions. [22][24]", "columns": [ "Complication", "Threshold or pattern", "Immediate diuretic action" ], "rows": [ [ "Hypovolemic hyponatremia", "Occurs during diuretic therapy. [24]", "Discontinue diuretics and expand plasma volume with normal saline. [24]" ], [ "Hypervolemic severe hyponatremia", "Serum sodium below 125 mmol/L. [24]", "Restrict fluids to 1-1.5 L/day. [24]" ], [ "Severely symptomatic acute hyponatremia", "Acute symptoms requiring urgent sodium correction. [24]", "Reserve 3% hypertonic saline; correct sodium slowly. [24]" ], [ "Encephalopathy, renal impairment, or electrolyte abnormalities attributable to diuretics", "Diuretic-induced complication in refractory ascites. [22]", "Discontinue diuretics permanently. [22]" ] ] } }, { "id": "escalate-refractory-ascites", "eyebrow": "Failure of diuresis", "heading": "Use paracentesis with albumin first, then select TIPS and transplant pathways", "intro": "Refractory ascites is a prognostic transition that should trigger procedural and transplant planning.", "paragraphs": [ "Refractory ascites carries poor short-term prognosis, with reported survival of 50% at 6 months and 25% at 1 year. [23] It should therefore trigger evaluation beyond repeated outpatient diuretic changes, including candidacy for TIPS and liver transplantation. [22][3]", "Repeated large-volume paracentesis plus albumin at 8 g per liter of ascites removed is first-line therapy for refractory ascites. [19][22] Large-volume paracentesis is safe and effective, with lower incidence of renal injury and electrolyte abnormalities and fewer systemic and hemodynamic disturbances than diuretics in the cited synthesis. [20] Continue using this approach when TIPS is contraindicated or deferred.", "Consider TIPS for refractory ascites, recurrent ascites, very frequent need for large-volume paracentesis, or ineffective paracentesis such as loculated ascites. [19][22] TIPS improves ascites control, but hepatic encephalopathy is an important tradeoff. [22] Use caution when age exceeds 70 years, bilirubin exceeds 50 µmol/L, platelet count is below 75 × 10^9/L, MELD score is at least 18, or the patient has current hepatic encephalopathy, active infection, or hepatorenal syndrome. [3]", "After TIPS, continue sodium restriction and diuretics until ascites resolves, with close clinical follow-up. [19] Where TIPS is selected, small-diameter PTFE-covered stents are recommended to reduce shunt dysfunction and to reduce hepatic encephalopathy risk in patients at high risk for encephalopathy. [19]" ], "bullets": [ "Use albumin 8 g/L of removed ascites with repeated large-volume paracentesis for refractory ascites. [19][22]", "Consider TIPS when paracentesis is required very frequently or is ineffective because of loculated ascites. [22]", "Use heightened caution before TIPS for MELD at least 18, bilirubin above 50 µmol/L, age above 70 years, active infection, hepatorenal syndrome, current encephalopathy, or platelets below 75 × 10^9/L. [3]", "Evaluate refractory or recurrent ascites for liver transplantation. [19][22]" ], "subsections": [ { "heading": "Role of adjunctive vasoconstrictor therapy", "paragraphs": [ "Midodrine may be considered case by case in refractory ascites. [24] An oral dose of 7.5 mg three times daily has been reported as beneficial when added to standard diuretic therapy, but this should not substitute for paracentesis, TIPS selection, or transplant evaluation when ascites remains refractory. [21]" ], "bullets": [] } ], "table": { "caption": "Escalation options after diuretic failure or intolerance. [19][22][3][24]", "columns": [ "Strategy", "When to use", "Key limitation or follow-up" ], "rows": [ [ "Repeated large-volume paracentesis plus albumin", "First-line treatment for refractory ascites. [19][22]", "Give albumin 8 g/L removed; repeat based on recurrence and symptoms. [19][22]" ], [ "TIPS", "Refractory/recurrent ascites, frequent paracentesis requirement, or ineffective paracentesis from loculation. [19][22]", "Consider encephalopathy risk and caution factors including MELD at least 18, active infection, or hepatorenal syndrome. [3][22]" ], [ "Midodrine", "Case-by-case adjunct in refractory ascites. [24]", "A reported regimen is 7.5 mg orally three times daily with standard diuretics. [21]" ], [ "Liver transplantation evaluation", "Refractory or recurrent ascites. [19][22]", "Proceed in parallel with symptom-control strategies rather than waiting for repeated diuretic failure. [19][22]" ] ] } }, { "id": "practical-follow-up", "eyebrow": "Longitudinal management", "heading": "Reassess response after every decompensating event and avoid futile diuretic exposure", "intro": "Ascites management should move promptly between diuretic-responsive and refractory pathways.", "paragraphs": [ "At each follow-up, document weight trajectory, peripheral edema, abdominal fluid burden, serum sodium, renal function, neurologic status, and urine sodium response when refractory ascites is being considered. A urine sodium excretion threshold above 30 mmol/day on diuretics distinguishes patients in whom maintenance diuretics may still be considered from those in whom they should be stopped. [22][19]", "When ascites has largely resolved, use the lowest effective diuretic dose and continue sodium restriction rather than preserving prior high doses. [20] When ascites recurs rapidly despite dietary restriction, medication escalation should not delay referral for serial large-volume paracentesis, TIPS assessment, and transplant evaluation. [23][19][22]", "For patients receiving nonselective beta-blockers, reassess blood pressure and kidney function concurrently with ascites therapy. Refractory ascites alone does not require beta-blocker discontinuation, but hypotension or acute/progressive renal dysfunction does. [24]" ], "bullets": [ "Use urine sodium greater than 30 mmol/day on treatment as the criterion supporting continued diuretics in refractory ascites. [22][19]", "Reduce diuretics after ascites control rather than maintaining the dose used for initial mobilization. [20]", "Escalate rapidly recurrent ascites to serial paracentesis, TIPS assessment, and transplant evaluation. [23][19][22]" ], "subsections": [], "table": { "caption": "Follow-up findings that change the next ascites-management step. [19][20][22][24]", "columns": [ "Follow-up finding", "Management change" ], "rows": [ [ "Ascites largely resolved", "Reduce diuretics to the lowest effective dose. [20]" ], [ "Urine sodium excretion greater than 30 mmol/day on diuretics in refractory ascites", "Maintenance diuretics may be considered if tolerated. [22][19]" ], [ "Urine sodium excretion not greater than 30 mmol/day in refractory ascites", "Stop diuretics and use repeated large-volume paracentesis plus albumin. [22][19]" ], [ "Hypotension or acute/progressive renal dysfunction while receiving a nonselective beta-blocker", "Reduce or discontinue the beta-blocker. [24]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Effect of Intravenous Albumin on Renal Impairment and Mortality in ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJM199908053410603", "authors": "www.nejm.org", "host": "www.nejm.org" }, { "number": 2, "title": "Diagnosis, prevention and treatment of hepatorenal syndrome ... - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/56/9/1310.full", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 3, "title": "Guidelines on the management of ascites in cirrhosis - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/early/2020/10/15/gutjnl-2020-321790.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 4, "title": "Recent advances in the prevention and treatment of decompensated ...", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/73/6/1015", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 5, "title": "Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement | Nature Reviews Clinical Oncology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41571-026-01160-z", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 6, "title": "Optimizing the liver transplant candidate | npj Gut and Liver - Nature", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s44355-024-00003-x", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 7, "title": "Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis: A combined prospective-retrospective study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-017-04895-z", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 8, "title": "Impact of physical activity on clinical outcomes in patients with liver cirrhosis: a prospective observational cohort study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-026-55248-8", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 9, "title": "Clinical Features of Refractory Ascites in Outpatients", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1807593222012121", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 10, "title": "Management of cirrhotic ascites: Seven‐step treatment protocol ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/hepr.13937", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 11, "title": "Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF) - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1590865821003352", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 12, "title": "The North American Study for the Treatment of Refractory Ascites - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S001650850215966X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "Ascites and Spontaneous Bacterial Peritonitis - Novel Coronavirus", "detail": "novel-coronavirus.onlinelibrary.wiley.com", "url": "https://novel-coronavirus.onlinelibrary.wiley.com/doi/pdf/10.1002/9781119950509.ch17", "authors": "novel-coronavirus.onlinelibrary.wiley.com", "host": "novel-coronavirus.onlinelibrary.wiley.com" }, { "number": 14, "title": "Management of adult patients with ascites due to cirrhosis", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.22853", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 15, "title": "Spontaneous bacterial peritonitis in asymptomatic outpatients with ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1053/jhep.2003.50119", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 16, "title": "SHM Converge 2026 Abstracts - Society of Hospital Medicine - Wiley", "detail": "shmpublications.onlinelibrary.wiley.com", "url": "https://shmpublications.onlinelibrary.wiley.com/doi/10.1002/jhm.70306", "authors": "shmpublications.onlinelibrary.wiley.com", "host": "shmpublications.onlinelibrary.wiley.com" }, { "number": 17, "title": "Management of adult patients with ascites due to cirrhosis - Runyon", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/hep.20066", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 18, "title": "Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S311781622600004X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "[PDF] EASL Clinical Practice Guidelines for the management of patients ...", "detail": "easl.eu", "url": "https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf", "authors": "easl.eu", "host": "easl.eu" }, { "number": 20, "title": "Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7805288", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 21, "title": "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6166105", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 22, "title": "[PDF] Hepatorenal-Cirrhosis-English-report.pdf - EASL", "detail": "easl.eu", "url": "https://easl.eu/wp-content/uploads/2018/10/Hepatorenal-Cirrhosis-English-report.pdf", "authors": "easl.eu", "host": "easl.eu" }, { "number": 23, "title": "Management of Refractory Ascites in Cirrhosis | AASLD", "detail": "www.aasld.org", "url": "https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/management-refractory-ascites-cirrhosis", "authors": "www.aasld.org", "host": "www.aasld.org" }, { "number": 24, "title": "Guidelines on the management of ascites in cirrhosis", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7788190", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Effect of Intravenous Albumin on Renal Impairment and Mortality in ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJM199908053410603", "authors": "www.nejm.org", "host": "www.nejm.org", "snippet": "Spontaneous bacterial peritonitis is a common and severe complication in patients with cirrhosis and ascites. It probably originates with the", "score": 0.4654124 }, { "number": 2, "title": "Diagnosis, prevention and treatment of hepatorenal syndrome ... - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/56/9/1310.full", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "TIPS can be used to improve refractory ascites, which is often associated with type-2 HRS. Data on the effect of TIPS on survival are still insufficient.", "score": 0.7206637 }, { "number": 3, "title": "Guidelines on the management of ascites in cirrhosis - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/early/2020/10/15/gutjnl-2020-321790.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Recommendations ► ► TIPSS should be considered in patients with refractory ascites. (Quality of evidence: high; Recommendation: strong) ► ► Caution is required if considering TIPSS in patients with age >70 years, serum bilirubin >50 µmol/L, platelet count <75×109/L, MELD core ≥18, current hepatic en", "score": 0.7132923 }, { "number": 4, "title": "Recent advances in the prevention and treatment of decompensated ...", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/73/6/1015", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association", "score": 0.6538572 }, { "number": 5, "title": "Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement | Nature Reviews Clinical Oncology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41571-026-01160-z", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Hepatic decompensation is a clinically significant outcome in patients with advanced-stage HCC135.\"). While preventing decompensation is crucial in managing cirrhosis and HCC, application of decompensation as a trial end point is challenging. Decompensation events such as ascites, bleeding or enceph", "score": 0.31846446 }, { "number": 6, "title": "Optimizing the liver transplant candidate | npj Gut and Liver - Nature", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s44355-024-00003-x", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nPubMed \nGoogle Scholar\n\nBiggins, S. W. et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1014–1048 (2021).\n\nArticle \nPubMed \n", "score": 0.6947383 }, { "number": 7, "title": "Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis: A combined prospective-retrospective study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-017-04895-z", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nCAS \nPubMed \nGoogle Scholar\n\nZarzycka, B. et al. Discovery of small molecule CD40-TRAF6 inhibitors. J. Chem. Inf. Model.\n55, 294–307 (2015).\n\nArticle \nCAS \nPubMed \nGoogle Scholar\n\nEuropean Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites", "score": 0.58777803 }, { "number": 8, "title": "Impact of physical activity on clinical outcomes in patients with liver cirrhosis: a prospective observational cohort study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-026-55248-8", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Variceal bleeding was defined as clinically evident upper gastrointestinal hemorrhage confirmed by endoscopy demonstrating bleeding esophageal or gastric varices. Ascites was diagnosed by clinical examination and ultrasonography. Hepatic encephalopathy was diagnosed according to West Haven criteria.", "score": 0.5300668 }, { "number": 9, "title": "Clinical Features of Refractory Ascites in Outpatients", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1807593222012121", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "187-192 )00188-000188-0) View PDFView articleCrossref00188-0)View in ScopusGoogle Scholar 16P Angeli, S Fasolato, E Mazza, L Okolicsanyi, G Maresio, E Velo, _et al._ Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clini", "score": 0.71377134 }, { "number": 10, "title": "Management of cirrhotic ascites: Seven‐step treatment protocol ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/hepr.13937", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Sodium restriction (and bed rest) improves ascites in only 10% of patients and therefore diuretics are usually required to improve therapeutic", "score": 0.56489134 }, { "number": 11, "title": "Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF) - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1590865821003352", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### J. Hepatol.\n\n### EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis\n\n### J Hepatol\n\n### EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis\n\n### J Hepatol\n\n### Adaptati", "score": 0.5515985 }, { "number": 12, "title": "The North American Study for the Treatment of Refractory Ascites - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S001650850215966X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Elsevier logo\nGastroenterology\n\n## Gastroenterology\n\n### Published by\n\nSociety Logo\n\n# Clinical–Liver, Pancreas, and Biliary Tract The North American Study for the Treatment of Refractory Ascites☆,☆☆,★,★★\n\n## Article preview\n\n## Abstract\n\n## Abbreviations\n\n## Organizational access\n\n### Other access ", "score": 0.34389287 }, { "number": 13, "title": "Ascites and Spontaneous Bacterial Peritonitis - Novel Coronavirus", "detail": "novel-coronavirus.onlinelibrary.wiley.com", "url": "https://novel-coronavirus.onlinelibrary.wiley.com/doi/pdf/10.1002/9781119950509.ch17", "authors": "novel-coronavirus.onlinelibrary.wiley.com", "host": "novel-coronavirus.onlinelibrary.wiley.com", "snippet": "r Abdominal paracentesis with ascitic fluid analysis is crucial in detecting the cause of ascites formation and in detecting ascitic fluid infection. This", "score": 0.57894874 }, { "number": 14, "title": "Management of adult patients with ascites due to cirrhosis", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.22853", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Abdominal paracentesis with appropriate ascitic fluid analysis is probably the most rapid and cost-effective method of diagnosing the cause of ascites.16,17", "score": 0.54840803 }, { "number": 15, "title": "Spontaneous bacterial peritonitis in asymptomatic outpatients with ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1053/jhep.2003.50119", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "SBP (neutrocytic ascites) was diagnosed in 15 of the patients based on paracentesis results. Six of the patients with SBP had positive ascitic fluid cultures,.", "score": 0.5407062 }, { "number": 16, "title": "SHM Converge 2026 Abstracts - Society of Hospital Medicine - Wiley", "detail": "shmpublications.onlinelibrary.wiley.com", "url": "https://shmpublications.onlinelibrary.wiley.com/doi/10.1002/jhm.70306", "authors": "shmpublications.onlinelibrary.wiley.com", "host": "shmpublications.onlinelibrary.wiley.com", "snippet": "Diagnostic paracentesis showed high SAAG, high protein ascites without evidence of infection or malignancy, making cirrhosis and peritoneal", "score": 0.539833 }, { "number": 17, "title": "Management of adult patients with ascites due to cirrhosis - Runyon", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/hep.20066", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Abdominal paracentesis with appropriate ascitic fluid analysis is probably the most rapid and cost-effective method of diagnosing the cause of", "score": 0.49538648 }, { "number": 18, "title": "Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S311781622600004X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Refractory ascites (RA) develops in approximately 10% of patients with cirrhotic ascites. The onset of RA heralds entry into a high-mortality-risk phase, characterized by a marked decline in 1-year survival rates, recurrent hospitalizations, worsening renal function, hyponatremia, spontaneous bacter", "score": 0.6391287 }, { "number": 19, "title": "[PDF] EASL Clinical Practice Guidelines for the management of patients ...", "detail": "easl.eu", "url": "https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf", "authors": "easl.eu", "host": "easl.eu", "snippet": "Recommendations \u0002 Repeated LVP plus albumin (8 g/L of ascites removed) are recommended as first line treatment for refractory ascites (I;1).\n\u0002 Diuretics should be discontinued in patients with refrac-tory ascites who do not excrete >30 mmol/day of sodium under diuretic treatment (III;1).\n\u0002 Although c", "score": 0.8173562 }, { "number": 20, "title": "Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7805288", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "#### Large-volume paracentesis\n\nRepeated LVP plus HA (8 g for a litre of ascites removed) are recommended as the first-line treatment for refractory ascites. This has been shown to be safe and effective with a low incidence of renal injury and electrolyte abnormalities and lesser systemic and haemod", "score": 0.8036831 }, { "number": 21, "title": "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6166105", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "When diuretic-resistant ascites develops, diuretics treatment is generally discontinued. The European Association for the Study of the Liver recommends discontinuing diuretics when urinary sodium excretion is < 30 mmol/day . As diuretic-resistant ascites is controlled by paracentesis thereafter, the", "score": 0.7890553 }, { "number": 22, "title": "[PDF] Hepatorenal-Cirrhosis-English-report.pdf - EASL", "detail": "easl.eu", "url": "https://easl.eu/wp-content/uploads/2018/10/Hepatorenal-Cirrhosis-English-report.pdf", "authors": "easl.eu", "host": "easl.eu", "snippet": "2.2.2. Diuretics in patients with refractory ascites In most patients (>90%), diuretics are not effective in preventing or delaying the recurrence of ascites after LVP since by definition patients have ascites which is refractory to diuretic therapy .\nDiuretics should be discontinued permanently in p", "score": 0.78154784 }, { "number": 23, "title": "Management of Refractory Ascites in Cirrhosis | AASLD", "detail": "www.aasld.org", "url": "https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/management-refractory-ascites-cirrhosis", "authors": "www.aasld.org", "host": "www.aasld.org", "snippet": "Inability to mobilize ascites despite adherence to dietary sodium restriction of 2 g per day and maximum tolerable doses of oral diuretics (spironolactone 400 mg/day and furosemide 160 mg/day; the caveat is that these doses are rarely reached due to adverse reactions); diuretic resistant ascites\n Ra", "score": 0.7722049 }, { "number": 24, "title": "Guidelines on the management of ascites in cirrhosis", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7788190", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "We conclude that, until randomised high-quality data are available, the current evidence supports the use of NSBB when indicated in patients with refractory ascites (online supplemental table 11), unless alternative markers of circulatory failure, such as hypotension or reduced glomerular filtration", "score": 0.76972175 } ], "publishedAt": "2026-09-15T22:08:15.833416+00:00", "updatedAt": "2026-09-15T22:08:15.833416+00:00", "readingMinutes": 6, "slug": "cirrhotic-ascites-diuretics" }